Trastuzumab duocarmazine - Synthon Biopharmaceuticals

Drug Profile

Trastuzumab duocarmazine - Synthon Biopharmaceuticals

Alternative Names: Anti-HER2 ADC SYD985; SYD 985; Trastuzumab vc-seco-DUBA

Latest Information Update: 08 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synthon
  • Developer Synthon; Yale University School of Medicine
  • Class Antineoplastics; Bacterial toxins; Cytostatic antibiotics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Small molecules
  • Mechanism of Action Alkylating agents; DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I Breast cancer; Gastric cancer; Solid tumours
  • Preclinical Gynaecological cancer
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 30 Aug 2017 Synthon Biopharmaceuticals plans a phase III trial for Breast cancer(Metastatic disease, Late-stage disease, Inoperable/unresectable) (NCT03262935)
  • 06 Jun 2017 Pharmacodynamic and pharmacokinetic data from a preclinical study in Gynaecological cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Apr 2017 Preclinical trials in Gynaecological cancer in Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top